Good for thank you Peter. you, afternoon today. us joining Thank and
are Wolter, Chief will operational and financial sold expenses performance our review Operating our we today achieving our operating goods Eduardo steps me of our and towards who taken CFO, Joining key Alvarez, who to Interim will positive Also, share cash Officer, Jonathan highlights have results. flow cost reduce results. operating
a company XXXX for take to has in role in his sincerely in appreciate on filing the company Jonathan procedures growth. with for week belt and his a start his the financial the of path take and Before putting appreciated where returning us our his CFO company making on expertise file much to place his I next his controls Jonathan past His his endeavor We in time. XX-K place compliance and Amyris stewardship fall to for efforts I in keeping to and I’d sincerely better. thank highly role level our and and continue, in a tireless will luck moment puts the wish in reporting like been mentoring next to we time partnership, to SEC this the
all time. I and during the face is coronavirus. impacting acknowledge I of also lives this uncertainty our greatly all appreciate attention the interest know of we this to fight with and I’d challenging global a our like reality and the shareholders against
supply who make priority up chain. has health time, and and this the teams, our safety our and been the collaborators the of customers serve our During we partners
have not business to very fortunate a impact been direct to have We experienced date.
carefully the very daily. is monitoring changing and it are situation We
directly impacted prayers wishes thoughts, well with those and a recovery. are Our for speedy
good start XXXX. our We very a our Clean a Beauty for met fourth business for experiencing critical deliver quarter targets Our activity. XXXX, and strong particularly, is
recurring very consider another a our operating doubling cash revenue proxy expect with for margin to we year strong adjusted flow. gross our of performance swing which We and EBITDA, positive significant
I’ll quarter focus performance, Clean Ingredients our then and my summarize and Eduardo. and to road before Beauty fourth results comments briefly review our ahead call XXXX casting then activity & on Health
a on Now share Total million; targets XXXX. related for let our XX% this gross at the $XXX the fourth We in GAAP guided revenue highlights We around was for to That quarter. was product million GAAP the $XXX for margin revenue of basis quarter of target. reported year $XXX.X $XX.X me $XX.X million. our delivered review at of royalty/value We XX% year of start and and delivered on the at and our business product sales number resulted million. revenue guided million. fourth the We full delivered to revenue. revenue XX% exceeded key of
revenue delivered three On doubled near sales a than to deliver We year to on guided molecules and recurring We about to this Clean gross we consecutive new million repeat gross are $XX to the third basis, sales more XXXX. guided and $XX three molecules new in we guided to million. and commercial $XX scaling track of margin. for and doubling XX% scale. at We million Beauty two were to
ingredients. number as by driven producer the of our is performance clean Our one role
are of is consumer what uniquely with which has delivering consecutive revenue leaders includes year are and doubling serving market that revenue, brands contract XXXX, demanding. all our third are for differentiated entering growth that from are markets consumers multi-year we that The Amyris partnerships a brands. and recurring our Our consumer high result revenue
quarter Health focus than Biossance and doubled on in commentary delivered Beauty record my business and sales activities focus year-over-year fourth the I’ll quarter. a Ingredients. more & of Clean two our Now
dollar best at invested was for the return on advertising our quarter, Our fourth $X.XX quarter-to-date.
the a including Biossance. the initiative in Daily, of Digital consumers. the Our in beauty has multiple Consumers of of within bible the which received and for awards industry, Year the Women’s is year, during trendsetting fashion. and The WWD, Clean Academy beauty Beauty Clean Innovator Sephora Wear as standard leadership become defining source educating Love brand at
growth. put one quarter brand on new many XX,XXX receiving the are accolades along fast day of XX,XXX with and fourth currently love is visitors influence consumers consumer received at We the track has a new This added in that biossance.com. Biossance and
countries. During to Biossance year expanded multiple the
destination where recently beauty UK, some must Biossance XX mouth, now have, The out. countries. outside America the North efficacy consumers serves Biossance includes shared and we This Biossance sold hits seeking influencer impressions based brand in our immediately UK the where on platform for Beauty, products in Consumers on the Cult of and products activity. have Biossance by the and been beauty launched word our media of
a and for In XXX Biossance we total to channel stores North continues solid showcase a stores exhibit out At offering stores XXX with our stores year wall Sephora mortar caps bricks generate end, display Biossance with products of sales America. of Sephora that the our These store of than times products. a just the within X to of full X.X per growth. few more were in
to XXXX. at a per in XXX% compared December measure its productivity which XXXX square hit December performs Biossance foot of is sales how in Our for of Sephora, to of peers. XXX% compared We
the current a Our doubled ago. of per about rate store sales are year
our offer. available the with space also significantly stores are number increasing to and full We of the sell
cosmetic due to dropped skincare quarter holiday markets, elevated the Normally, within substantially sales fourth gifting. and following are the and they
date Our to has outstanding. first been quarter
revenue have of the invested $X.X.X generating now Sephora productivity of for store reached every inside are advertising and dollar XXX%. We
for brand Sephora. is garnering open is from XXX% currently quarter revenue support displayed traditional alone. driving and biossance.com performance the be stores last them XXX% year XXX the its running at even These XXXX. sales malls of in and Sephora with store to to to be Biossance planned growth for first those stores smaller greater is each prominently to Biossance will over XXXX this beyond And date plan Biossance’s will at begun growth. and of biggest has outside year. expansion
distributed range winning. its Pipette, online baby Biossance. that target.com Pipette for of skincare our across revenue is is With first brand this with of broaden Pipette to around to full launched channels first we channel. on XX% our report is about on of than year a making track million strategy revenue pleased year $X year recently full better I’m our
Also Squalane about the it’s result our improving value, their global captured our hero formulas. at the highest best that we Squalane is ingredients efficacy the of the The in volume is purity finding record are Brands have XXXX. also had that but Squalane of in in position ingredient Clean that majority market. XX% Beauty, active a of
while in We in ingredient expanding continuing to Squalane global a the are share. $XX Squalane, million our grow alone single approaching annual for is size sales. as successfully market
XXXX expected Most gross XXXX the around channel. and million of for sales revenue. Beauty in number difference gross sales The represents about of is $XX is and to Clean million of $XXX the the to in $XX GAAP tracking delivered wholesale sales our about discount revenue This that XXXX gross Sephora. sales really is XXXX. between GAAP million
Let take & minutes to cover few me Ingredients Health business. our a
to ingredients are flavor fragrance and supplied mostly Our industry. the
continued more to XXXX half in their existing revenue. sales We in fragrance million of ingredients of experiencing and that expect double we a over from from a ingredients than year have growth to is new strong sales. other $XX growth XXXX year in ingredient full first XXXX and industry and the The the half flavors are
Givaudan, the flavor deep and pipeline with relationship the natural cane Cannabinoid health and launch ingredients industry have activity sugar We we wellness and our Firmenich focused partner of in and cane, in strong strategic a And zero on industry. part sweetener calorie the two that leaders to and the business, continue from with a our LAVVAN. of new and are enjoy pure our of our fragrance
address a advanced significantly solution supply minutes. I to of cover to the also will a this vaccines. with flu have in need breakthrough We increase few the
our sampled actively about XXX in of launched group engaged or we purchasing customers the with Since XX% this we product. sweetener, formulations have
has XX% been performance where have America, the product. Latin the or purchasing best formulate start date specs decided to Our product to sample of
Latin the We remain are marketsm, sold across expect wins XXXX. late scoring to until Brazil including American out major and
our takes and work it’s selling built. to are for as We are brands factory time with before new we continuing on focused adoption it out new
new is the not factory, The to ingredients open in referring first our factory, of sweetener specialty expect the we to I’m XXXX. which half factory
Our relationship continues This well. market cannabinoids go wellness development and other with LAVVAN. our health and significant to is very for
LAVVAN. through partner molecules We are first year scale expecting working to two our our this
of topical for the our been chassis has had the from a CBD making become about market our becoming the formulations. excited significant leading consumer. to leading is ingredient Squalane another making natural view and for the as leading example the for opportunity industry this powerful formulations CBD information all the sustainable platform this oil discovery beauty We applications very as inquiries opportunity are CBD molecule since this the how public. to Squalane responding We of view to We believe of and number as the for better
In the the stay with as be CPG are use skin had with our partnership tuned for some Squalane learnings clinical ingredients. that also breakthrough, addition on one success initial LAVVAN to currently leading the world, Cannabinoid. transformative skincare labs they in of these of CBG in and insights our our and And we’ve and topical breakthrough testing CBG as a commercialize for applications, of of could active for
with White XXXX, of industry United along In House the strategic I States. role the to biology the leaders synthetic discuss was invited for to other
in volumes significant major at areas pandemic a of focus need of time and concern the the of the vaccines of to the risk government was significant flu of the House the in flu White from the this to major pandemic. make agencies One case available several
adjuvants. human within help we I beauty do market, shark the for is help industry being Squalene and turbocharge needs administered. briefing, vaccines back vaccine this they the solve body’s in Outside effective our to support used team used liver the essentially what the government. explored could Squalane, Adjuvants and based After the with but response of pharmaceutical our with and to came not are the Squalene, to medication of
It’s carrier Almost same to Squalene like think oil carrier. for is the we best that of the CBD. body. carrier the it Think Squalane vaccines best example a the of almost for as that human discovered
Melinda Disease save a sugarcane for our with on of use IDRI Gates vaccines Research years the focus received Foundation working the the been program the from of to evaluate funding as with a have IDRI in We Institute lives. & Infectious or on availability Bill prior to adjuvants. increasing Squalene
flu becomes for when short availability been it approval the to be light new usually and help significant engaging so are to in a one is you in of This unlimited doses acceleration quantities regulatory limited can term vaccine would Sugarcane-based it XXX can of be available. the current limited adjuvants due source support limitations and also use meet the XXXX. vaccines. support of expensive. XX% to in over is availability like and performing can its be if we flu vaccines Squalene of needs million we could our is best and of the deployment pandemic its scaling Squalene the coronavirus since vaccine and and shark relevant in of delivering available than stakeholders achieving costs that of has ready being We lower used Squalene a to animal important is when source; needed. made very use
The initial similar equal a Squalene harmful – biology very than sugarcane-based approach have in material. health our lives to shark-based global anti-malarial performance anti-material with from our impurities our are shark-based just as our better This an of could vital IDRI without it focused the Squalene delivers a Squalene in play anti-malarial role data can the We treatment test has demonstrated we saving the or adjuvant reality. as potential making application as on did this is did a synthetic with and to artemisinin. role we with think
approval the to solution ensure when a deploy and biosimilar perspective, our current this approach vaccine believe can be for very track a regulatory FDA approval by treated a available to pandemic. fast be we the would fast part we regulatory A as it’s be would of to deploy from
have the me long-term Since and raised another Let year, started to sheet. from with have We balance strong million, the transition. start $XX our operational improving of mostly performance the investors. step we the taken year very successfully
equity. most of and equity that that converted continue with portion to of being a was warrants We
We long-term holders. from continue have very to strong support our
long-term our core delivering the these of are and performance Some our of holders we are board aware on and markets. are across traction transformative
reduced our period. also We million about by this debt $XX during
and markets, down significantly We resilient of are leading of beauty, the health on recession. where some clean advantaged ingredients. that sustainable we are technology brands. and These from have These periods are molecules doubling markets world’s and platform market are
improving are between million by our $XXX adjusted We and over EBITDA XXXX. XXXX
of our other XX% the detail. us in expect We in goods, increasing market DSM. and cost cost Eduardo half reductions, cost reductions from growth. are will cover improvements mostly this and and brought major sales our production about with or shareholder, from more from of from half The improvement partner improvements and growth this that
of are XX% traction from on to already reduction we other The realizing opex, both these.
$XX to year for and quarter about margin last the is an OpEx positive million We first are better from experiencing swing our slightly our in gross than plan the year.
better key So, or XXXX? $XXX First, targets what are for for our we expect the total revenue in year. million
our We $XX targets. on minimum in have $XX uncertainty as to guidance from upside million have not our is focused included that million XXXX removing we of
be We and XX% expect our between gross XX%. to margin
We expect three new commercialized a molecules. two to
at period China We CMO product our from our coronavirus supplier any material a not We impact for pandemic. the inventory down have now from experienced shut have did it We the enough the to impact a supplier not key in direct did business. normal. back and had and was that mostly is for
this evolve monitoring carefully continues daily. as are situation to We the
a We are sheet of and balance solid we the in with that behind accounting XXXX a operating us performance now. are issues excited about combined year faced better
Let me to Eduardo. Eduardo? turn
